The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Male or female, aged ≥18 years.
Willing and able to give written, informed consent.
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1.
Relapsed or refractory lymphoblastic leukemia/lymphoma.
Females who are pregnant or lactating.
History or presence of clinically relevant CNS pathology such as epilepsy, paresis, aphasia, stroke within prior 3 months, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, or psychosis.
Patients with active CNS involvement by malignancy. Patients with history of central nervous system (CNS) involvement with malignancy may be eligible if CNS disease has been effectively treated and provided treatment was at least 4 weeks prior to enrolment (at least 8 weeks prior to CAR-T infusion).
Clinically significant, uncontrolled heart disease or a recent (within 12 months) cardiac event.